Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Former FDA Official Calls For 483 Reforms, Notes Caveats

Executive Summary

Public scrutiny has made 483 results much more impactful than intended, says Howard Sklamberg, former FDA deputy commissioner for global regulatory operations and policy. He reminds stakeholders that information in them is preliminary.

You may also be interested in...



Former FDA official Sklamberg On Objectivity In 483s, Assessing Quality Culture

Former US FDA Deputy Commissioner for Global Regulatory Operations and Policy, Howard Sklamberg, shares his views at a conference in India on a range of issues, including the need for formal policy mechanisms to help infuse improved objectivity around Form 483 observations and challenges on evaluating quality culture.

US FDA Threatens Fines For ClinicalTrials.gov Noncompliance

Draft guidance states that "responsible parties" could be fined $10,000 for not submitting trial information to the federal data repository as required by law.

FDA Warns Apotex Management To Demand Quality, Meet Specs

Apotex warning letter reflects FDA’s emphasis on company-wide quality systems and invalidated OOS results.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS123739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel